Data Sheet (Cat.No.TMAY-00781)

TargetMol

Anti-DR4/TRAIL R1 Antibody (3R561)

Product Details

Ig Type:	Rabbit IgG
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	3R561
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Human TNFRSF10A(CD261) on HeLa cells. Cells were stained with purified anti-Human TNFRSF10A(CD261) (Filled hisgram), then stained with a FITC-conjugated second step antibody. To demonstrate specificity of staining, the binding by Anti-DR4/TRAIL R1 Antibody was blocked by preincubation of the purified antibody with 20ug recombinant human TNFRSF10A(CD261) for 1 hour (Black solid line hisgram).
Application:	FCM
Recommended	FCM: 1:25-1:100

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human TRAIL R1 / CD261 / TNFRSF10A Protein (TMPY-01720)
Antigen Species:	Human
Synonyms:	DR4;TNFRSF10A;tumor necrosis factor receptor superfamily member 10a;TRAILR1;TRAILR-1;APO2;CD261;MGC9365
Biology Area:	Cancer Drug Targets

Research Background

Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481